Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors.
Kesteleyn B, Bardiot D, Bonfanti JF, De Boeck B, Goethals O, Kaptein SJF, Stoops B, Coesemans E, Fortin J, Muller P, Doublet F, Carlens G, Koukni M, Smets W, Raboisson P, Chaltin P, Simmen K, Van Loock M, Neyts J, Marchand A, Jonckers THM. Kesteleyn B, et al. Among authors: fortin j. J Med Chem. 2023 Jul 13;66(13):8808-8821. doi: 10.1021/acs.jmedchem.3c00403. Epub 2023 Jun 30. J Med Chem. 2023. PMID: 37389813
Synthesis and biological evaluation of 1,2,4-triazinylphenylalkylthiazolecarboxylic acid esters as cytokine-inhibiting antedrugs with strong bronchodilating effects in an animal model of asthma.
Freyne EJ, Lacrampe JF, Deroose F, Boeckx GM, Willems M, Embrechts W, Coesemans E, Willems JJ, Fortin JM, Ligney Y, Dillen LL, Cools WF, Goossens J, Corens D, De Groot A, Van Wauwe JP. Freyne EJ, et al. Among authors: fortin jm. J Med Chem. 2005 Mar 24;48(6):2167-75. doi: 10.1021/jm049479m. J Med Chem. 2005. PMID: 15771459
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.
Bonfanti JF, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Janssens F, Sommen C, Wigerinck P, Andries K. Bonfanti JF, et al. Among authors: fortin j. J Med Chem. 2007 Sep 20;50(19):4572-84. doi: 10.1021/jm070143x. Epub 2007 Aug 28. J Med Chem. 2007. PMID: 17722899
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K. Bonfanti JF, et al. Among authors: fortin j. J Med Chem. 2008 Feb 28;51(4):875-96. doi: 10.1021/jm701284j. Epub 2008 Feb 7. J Med Chem. 2008. PMID: 18254606
Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor.
Kesteleyn B, Bonfanti JF, Bardiot D, De Boeck B, Goethals O, Kaptein SJF, Stoops B, Coesemans E, Fortin J, Muller P, Doublet F, Carlens G, Koukni M, Smets W, Raboisson P, Chaltin P, Simmen K, Loock MV, Neyts J, Marchand A, Jonckers THM. Kesteleyn B, et al. Among authors: fortin j. J Med Chem. 2024 Mar 14;67(5):4063-4082. doi: 10.1021/acs.jmedchem.3c02336. Epub 2024 Feb 28. J Med Chem. 2024. PMID: 38482827
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free article. Clinical Trial.
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R, Weisman HR, Gonzalez Castro LN, Druck N, Chanoch-Myers R, Lee JJY, Mylvaganam R, Lee Servis R, Fung JM, Lee CK, Nagashima H, Miller JJ, Arrillaga-Romany I, Louis DN, Wakimoto H, Pisano W, Wen PY, Mak TW, Sanson M, Touat M, Landau DA, Ligon KL, Cahill DP, Suvà ML, Tirosh I. Spitzer A, et al. Among authors: fortin j. Cancer Cell. 2024 May 13;42(5):904-914.e9. doi: 10.1016/j.ccell.2024.03.008. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579724 Free article.
485 results